Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Diabetology & Metabolic Syndrome
Published in: Diabetology & Metabolic Syndrome 1/2023

Open Access 01-12-2023 | Prediabetes | Research

Endocan in prediabetes, diabetes, and diabetes-related complications: a systematic review and meta-analysis

Authors: Amirmohammad Khalaji, Amir Hossein Behnoush, Behrad Saeedian, Shaghayegh Khanmohammadi, Zahra Shokri Varniab, Soheil Peiman

Published in: Diabetology & Metabolic Syndrome | Issue 1/2023

Login to get access

Abstract

Background

Diabetes is one of the chronic conditions with a high burden all around the world. Macrovascular and microvascular involvement are among the common mechanisms by which diabetes can impact patients’ lives. Endocan as an inflammatory endothelial biomarker has been shown to increase in several communicable and non-communicable diseases. Herein, we aim to investigate the role of endocan as a biomarker in diabetes as a systematic review and meta-analysis.

Methods

International databases, including PubMed, Web of Science, Scopus, and Embase were searched for relevant studies assessing blood endocan in diabetic patients. Estimation of the standardized mean difference (SMD) and 95% confidence interval (CI) for comparison of circulating endocan levels between diabetic patients and non-diabetic controls were conducted through random-effect meta-analysis.

Results

Totally, 24 studies were included, assessing 3354 cases with a mean age of 57.4 ± 8.4 years. Meta-analysis indicated that serum endocan levels were significantly higher in diabetic patients in comparison with healthy controls (SMD 1.00, 95% CI 0.81 to 1.19, p-value < 0.01). Moreover, in the analysis of studies with only type-2 diabetes, the same result showing higher endocan was obtained (SMD 1.01, 95% CI 0.78 to 1.24, p-value < 0.01). Higher endocan levels were also reported in chronic diabetes complications such as diabetic retinopathy, diabetic kidney disease, and peripheral neuropathy.

Conclusion

Based on our study’s findings, endocan levels are increased in diabetes, however, further studies are needed for assessing this association. In addition, higher endocan levels were detected in chronic complications of diabetes. This can help researchers and clinicians in recognizing disease endothelial dysfunction and potential complications.
Appendix
Available only for authorised users
Literature
1.
Patterson CC, Harjutsalo V, Rosenbauer J, Neu A, Cinek O, Skrivarhaug T, et al. Trends and cyclical variation in the incidence of childhood type 1 diabetes in 26 european centres in the 25 year period 1989–2013: a multicentre prospective registration study. Diabetologia. 2019;62(3):408–17.PubMedCrossRef
2.
Dwyer-Lindgren L, Mackenbach JP, van Lenthe FJ, Flaxman AD, Mokdad AH. Diagnosed and undiagnosed diabetes prevalence by County in the U.S., 1999–2012. Diabetes Care. 2016;39(9):1556–62.PubMedCrossRef
3.
4.
Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.PubMedCrossRef
5.
Long J, Yang Z, Wang L, Han Y, Peng C, Yan C, et al. Metabolite biomarkers of type 2 diabetes mellitus and pre-diabetes: a systematic review and meta-analysis. BMC Endocr Disord. 2020;20(1):174.PubMedPubMedCentralCrossRef
6.
7.
Xu Y, Wang L, He J, Bi Y, Li M, Wang T, et al. Prevalence and control of diabetes in chinese adults. JAMA. 2013;310(9):948–59.PubMedCrossRef
8.
9.
Paschou SA, Papadopoulou-Marketou N, Chrousos GP, Kanaka-Gantenbein C. On type 1 diabetes mellitus pathogenesis. Endocr Connect. 2018;7(1):R38–r46.PubMedCrossRef
10.
Maruhashi T, Higashi Y. Pathophysiological Association between Diabetes Mellitus and Endothelial Dysfunction. Antioxid (Basel). 2021;10(8).
11.
Zhang J. Biomarkers of endothelial activation and dysfunction in cardiovascular diseases. Rev Cardiovasc Med. 2022;23(2):73.PubMedCrossRef
12.
Balta S, Demirkol S, Celik T, Kucuk U, Unlu M, Arslan Z, et al. Association between coronary artery ectasia and neutrophil–lymphocyte ratio. Angiology. 2013;64(8):627–32.PubMedCrossRef
13.
14.
Arman Y, Akpinar TS, Kose M, Emet S, Yuruyen G, Akarsu M, et al. Effect of glycemic regulation on endocan levels in patients with diabetes: a preliminary study. Angiology. 2016;67(3):239–44.PubMedCrossRef
15.
Huang X, Chen C, Wang X, Zhang JY, Ren BH, Ma DW, et al. Prognostic value of endocan expression in cancers: evidence from meta-analysis. Onco Targets Ther. 2016;9:6297–304.PubMedPubMedCentralCrossRef
16.
Li C, Geng H, Ji L, Ma X, Yin Q, Xiong H. ESM-1: a Novel Tumor Biomaker and its research advances. Anticancer Agents Med Chem. 2019;19(14):1687–94.PubMedCrossRef
17.
Leite AR, Borges-Canha M, Cardoso R, Neves JS, Castro-Ferreira R, Leite-Moreira A. Novel biomarkers for evaluation of endothelial dysfunction. Angiology. 2020;71(5):397–410.PubMedCrossRef
18.
Balta S, Mikhailidis DP, Demirkol S, Ozturk C, Celik T, Iyisoy A. Endocan: a novel inflammatory indicator in cardiovascular disease? Atherosclerosis. 2015;243(1):339–43.PubMedCrossRef
19.
Icli A, Cure E, Cure MC, Uslu AU, Balta S, Mikhailidis DP, et al. Endocan levels and subclinical atherosclerosis in patients with systemic Lupus Erythematosus. Angiology. 2016;67(8):749–55.PubMedCrossRef
20.
Khalaji A, Amirkhani N, Sharifkashani S, Peiman S, Behnoush AH. Systematic Review of Endocan as a Potential Biomarker of COVID-19. Angiology. 2023:00033197231152941.
21.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):89.PubMedPubMedCentralCrossRef
22.
Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Oxford; 2000.
23.
Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377–84.PubMedPubMedCentralCrossRef
24.
Ratcliffe E, Pickering S, McLean S, Lewis J. Is there a relationship between subacromial impingement syndrome and scapular orientation? A systematic review. Br J Sports Med. 2014;48(16):1251–6.PubMedCrossRef
25.
Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. Fam Med. 2005;37(5):360–3.PubMed
26.
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–6.PubMedPubMedCentralCrossRef
27.
Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018;27(6):1785–805.PubMedCrossRef
28.
Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.PubMedPubMedCentralCrossRef
29.
30.
31.
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101.PubMedCrossRef
32.
Anlk A, Çelik E, Çevik Ö, Ünüvar T, Anlk A. The relation of serum endocan and soluble endoglin levels with metabolic control in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2020;33(8):1013–8.CrossRef
33.
Arman Y, Akpinar TS, Kose M, Emet S, Yuruyen G, Akarsu M, et al. Effect of glycemic regulation on endocan levels in patients with diabetes. Angiology. 2016;67(3):239–44.PubMedCrossRef
34.
Arman Y, Atici A, Altun O, Sarikaya R, Yoldemir SA, Akarsu M, et al. Can the serum Endocan Level be used as a Biomarker to predict subclinical atherosclerosis in patients with Prediabetes? Arq Bras Cardiol. 2022;119(4):544–50.PubMedPubMedCentral
35.
Balamir I, Ates I, Topcuoglu C, Turhan T. Association of Endocan, Ischemia-Modified albumin, and hsCRP levels with endothelial dysfunction in type 2 diabetes Mellitus. Angiology. 2018;69(7):609–16.PubMedCrossRef
36.
Bilir B, Ekiz Bilir B, Yilmaz I, Soysal Atile N, Yildirim T, Kara SP, et al. Association of apelin, endoglin and endocan with diabetic peripheral neuropathy in type 2 diabetic patients. Eur Rev Med Pharmacol Sci. 2016;20(5):892–8.PubMed
37.
Bingol Z, Kose M, Pihtili A, Akpinar T, Tukek T, Kiyan E. Serum endothelial cell specific molecule-1 (endocan) levels in patients with obstructive sleep apnea. Biomarkers Med. 2016;10(2):177–84.CrossRef
38.
Bozkurt E, Gumus A, Koban Y. Can serum endocan level predict stage of diabetic retinopathy? Retina-Vitreus. 2020;29(4):318–23.CrossRef
39.
Celik F, Aydin S. Blood and aqueous humor phoenixin, endocan and spexin in patients with diabetes mellitus and cataract with and without diabetic retinopathy. Peptides. 2022;150.
40.
Chang LH, Hwu CM, Chu CH, Lin YC, Huang CC, You JY, et al. The combination of soluble tumor necrosis factor receptor type 1 and fibroblast growth factor 21 exhibits better prediction of renal outcomes in patients with type 2 diabetes mellitus. J Endocrinol Invest. 2021;44(12):2609–19.PubMedCrossRef
41.
Chen Z, Yuan K, Yan R, Yang H, Wang X, Wang Y, et al. The role of endothelial biomarkers in predicting damp-heat syndrome in diabetic kidney disease. J Tradit Chin Med Sci. 2022;9(1):34–9.
42.
Cikrikcioglu MA, Erturk Z, Kilic E, Celik K, Ekinci I, Yasin Cetin AI, et al. Endocan and albuminuria in type 2 diabetes mellitus. Ren Fail. 2016;38(10):1647–53.PubMedCrossRef
43.
Dallio M, Masarone M, Caprio GG, Di Sarno R, Tuccillo C, Sasso FC, et al. Endocan serum levels in patients with non-alcoholic fatty liver disease with or without type 2 diabetes mellitus: a pilot study. J Gastrointest Liver Dis. 2017;26(3):261–8.CrossRef
44.
Ekiz-Bilir B, Bilir B, Aydın M, Soysal-Atile N. Evaluation of endocan and endoglin levels in chronic kidney disease due to diabetes mellitus. Archives of Medical Science. 2019;15(1):86–91.PubMedCrossRef
45.
Elkamshoushi AAM, Hassan EM, El Abd AM, Hassan SZ, Maher AA. Serum endocan as a predictive biomarker of cardiovascular risk in erectile dysfunction patients. Andrologia. 2018;50(10).
46.
Kim JS, Ko GJ, Kim YG, Lee SY, Lee DY, Jeong KH, et al. Plasma endocan as a predictor of cardiovascular event in patients with end-stage renal disease on hemodialysis. J Clin Med. 2020;9(12):1–10.CrossRef
47.
Klisic A, Kavaric N, Stanisic V, Vujcic S, Spasojevic-Kalimanovska V, Ninic A, et al. Endocan and a novel score for dyslipidemia, oxidative stress and inflammation (DOI score) are independently correlated with glycated hemoglobin (HbA1c) in patients with prediabetes and type 2 diabetes. Archives of Medical Science. 2020;16(1):42–50.PubMedCrossRef
48.
Klisic A, Kavaric N, Vujcic S, Mihajlovic M, Zeljkovic A, Ivanisevic J, et al. Inverse association between serum endocan levels and small LDL and HDL particles in patients with type 2 diabetes mellitus. Eur Rev Med Pharmacol Sci. 2020;24(15):8127–35.PubMed
49.
Kose M, Emet S, Akpinar TS, Kocaaga M, Cakmak R, Akarsu M, et al. Serum Endocan Level and the severity of coronary artery disease. Angiology. 2015;66(8):727–31.PubMedCrossRef
50.
Kosir G, Jug B, Novakovic M, Mijovski MB, Ksela J. Endocan is an independent predictor of heart failure-related mortality and hospitalizations in patients with chronic stable heart failure. Dis Markers. 2019;2019.
51.
Lv YY, Zhang YQ, Shi WY, Liu JX, Li YH, Zhou ZB, et al. The Association between Endocan levels and subclinical atherosclerosis in patients with type 2 diabetes Mellitus. Am J Med Sci. 2017;353(5):433–8.PubMedCrossRef
52.
Moin ASM, Sathyapalan T, Atkin SL, Butler AE. Diagnostic and Prognostic Protein Biomarkers of β-Cell Function in Type 2 Diabetes and Their Modulation with Glucose Normalization. Metabolites. 2022;12(3).
53.
Qiu CR, Fu Q, Sui J, Zhang Q, Wei P, Wu Y, et al. Analysis of serum endothelial cell-specific molecule 1 (endocan) level in type 2 diabetes Mellitus with Acute ST-Segment Elevation myocardial infarction and its correlation. Angiology. 2017;68(1):74–8.PubMedCrossRef
54.
Singh R, Goyal S, Aggarwal N, Mehta S, Kumari P, Singh V, et al. Study on dengue severity in diabetic and non-diabetic population of tertiary care hospital by assessing inflammatory indicators. Ann Med Surg (Lond). 2022;82:104710.PubMed
55.
Zuwala-Jagiello J, Pazgan-Simon M, Simon K, Kukla M, Murawska-Cialowicz E, Grzebyk E. Serum endocan level in diabetes mellitus of patients with cirrhosis and risk of subsequent development of spontaneous bacterial peritonitis. J Physiol Pharmacol. 2019;70(3):399–405.
56.
Balta S, Balta I, Mikhailidis DP. Endocan: a new marker of endothelial function. Curr Opin Cardiol. 2021;36(4):462–8.PubMedCrossRef
57.
Chen J, Jiang L, Yu XH, Hu M, Zhang YK, Liu X, et al. Endocan: a key player of Cardiovascular Disease. Front Cardiovasc Med. 2021;8:798699.PubMedCrossRef
58.
Takeda Y, Matoba K, Sekiguchi K, Nagai Y, Yokota T, Utsunomiya K et al. Endothelial Dysfunction in Diabetes. Biomedicines. 2020;8(7).
59.
Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004;109(23 Suppl 1):Iii27–32.PubMed
60.
Kirpichnikov D, Sowers JR. Diabetes mellitus and diabetes-associated vascular disease. Trends Endocrinol Metab. 2001;12(5):225–30.PubMedCrossRef
61.
Gui F, You Z, Fu S, Wu H, Zhang Y. Endothelial dysfunction in Diabetic Retinopathy. Front Endocrinol (Lausanne). 2020;11:591.PubMedCrossRef
62.
Maiuolo J, Gliozzi M, Musolino V, Carresi C, Nucera S, Macrì R et al. The Role of Endothelial Dysfunction in Peripheral Blood Nerve Barrier: Molecular Mechanisms and Pathophysiological Implications. Int J Mol Sci. 2019;20(12).
63.
64.
Bozkurt E, Çakır B, Çelik E, Doğan E, Uçak T, Alagöz G. Correlation of the aqueous humor total antioxidant capacity, total oxidant status, and levels of IL-6 and VEGF with diabetic retinopathy status. Arq Bras Oftalmol. 2019;82(2):136–40.PubMedCrossRef
65.
Abu El-Asrar AM, Nawaz MI, De Hertogh G, Al-Kharashi AS, Van Den Eynde K, Mohammad G, et al. The angiogenic biomarker endocan is upregulated in proliferative diabetic retinopathy and correlates with vascular endothelial growth factor. Curr Eye Res. 2015;40(3):321–31.PubMedCrossRef
66.
Nalewajska M, Gurazda K, Marchelek-Myśliwiec M, Pawlik A, Dziedziejko V. The role of Endocan in selected kidney Diseases. Int J Mol Sci. 2020;21:17.CrossRef
Metadata
Title
Endocan in prediabetes, diabetes, and diabetes-related complications: a systematic review and meta-analysis
Authors
Amirmohammad Khalaji
Amir Hossein Behnoush
Behrad Saeedian
Shaghayegh Khanmohammadi
Zahra Shokri Varniab
Soheil Peiman
Publication date
01-12-2023
Publisher
BioMed Central
Keyword
Prediabetes
Published in
Diabetology & Metabolic Syndrome / Issue 1/2023
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/s13098-023-01076-z

Other articles of this Issue 1/2023

Diabetology & Metabolic Syndrome 1/2023 Go to the issue

Brief Report

Fasting hepatic insulin clearance reflects postprandial hepatic insulin clearance: a brief report

Research

Association of a history of gestational diabetes mellitus with osteoporosis, bone mineral density, and trabecular bone score in postmenopausal women

Research

Caffeine ameliorates the metabolic syndrome in diet-induced obese mice through regulating the gut microbiota and serum metabolism

Research

The triglyceride-glucose index as a potential protective factor for hypertrophic obstructive cardiomyopathy without diabetes: evidence from a two-center study

Research

Plasma aryl hydrocarbon receptor associated with epicardial adipose tissue in men: a cross-sectional study

Research

MiniMed 780G™ advanced hybrid closed-loop system performance in Egyptian patients with type 1 diabetes across different age groups: evidence from real-world users
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits